Literature DB >> 24370708

Evaluation of humoral and cellular immune responses to BP26 and OMP31 epitopes in the attenuated Brucella melitensis vaccinated sheep.

Wenjing Wang1, Jingbo Wu1, Jun Qiao2, Yunceng Weng1, Hui Zhang2, Qingyu Liao1, Jinlang Qiu1, Chuangfu Chen2, Jean-Pierre Allain3, Chengyao Li4.   

Abstract

In recent years, the number of cases of human brucellosis has been increasing by approximately 10% per year in China. Most cases were caused by Brucella melitensis through contacts with infected sheep, goats or their products. An attenuated B. melitensis vaccine M5-90 is currently used to vaccinate both animals in China. This vaccine has not been investigated for critical parameters such as immune response and its association with protective efficacy. In this study, humoral and cellular immune response to the periplasmic protein BP26 and the outer membrane protein OMP31 were evaluated in M5-90 vaccinated Chinese merino and Kazak sheep. Antibodies to BP26 or OMP31 were detected at low levels, and specific IFN-γ response was quantified. Strongly reactive peptides derived from BP26 and OMP31 identified five T-cell epitopes (BP26-6, -8, -11, -12 and OMP31-23) common to both sheep species, five species-specific epitopes (BP26-10, -18, -21 and -22 and OMP31-12) and four animal-specific epitopes (BP26-15, -23, OMP31-6 and -21), which stimulated specific IFN-γ response in vaccinated sheep. Among those T-cell epitopes, reactivity to BP26-18 and -21 epitopes was significantly associated with MHC-I B allele (P=0.024). However, a specific T-cell response induced by the M5-90 vaccine was relatively week and did not sustain long enough, which might be suppressed by rapid activation of T-regulatory (Treg) cells following vaccination. These findings provide an insight in designing a safer and more effective vaccine for use in animals and in humans.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  B. melitensis; BP26; Epitopes; Immune Response; OMP31; Vaccine

Mesh:

Substances:

Year:  2013        PMID: 24370708     DOI: 10.1016/j.vaccine.2013.12.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Immune reactivity of sera obtained from brucellosis patients and vaccinated-rabbits to a fusion protein from Brucella melitensis.

Authors:  Jafar Amani; Amir Ghasemi; Reza Ranjbar; Mahdi Shabani; Mahdi Zandemami; Reza Golmohammadi
Journal:  Iran J Basic Med Sci       Date:  2015-04       Impact factor: 2.699

2.  Immunoreactivity evaluation of a new recombinant chimeric protein against Brucella in the murine model.

Authors:  Abbas Abdollahi; Shahla Mansouri; Jafar Amani; Mahdi Fasihi-Ramandi; Mohammad Moradi
Journal:  Iran J Microbiol       Date:  2016-06

3.  Characterization of novel Omp31 antigenic epitopes of Brucella melitensis by monoclonal antibodies.

Authors:  Jinfeng Li; Feihuan Hu; Shouyi Chen; Peifang Luo; Zuoping He; Wenjing Wang; Jean-Pierre Allain; Chengyao Li
Journal:  BMC Microbiol       Date:  2017-05-15       Impact factor: 3.605

Review 4.  Meta-Analysis of the Changes of Peripheral Blood T Cell Subsets in Patients with Brucellosis.

Authors:  Rongjiong Zheng; Songsong Xie; Shaniya Niyazi; Xiaobo Lu; Lihua Sun; Yan Zhou; Yuexin Zhang; Kai Wang
Journal:  J Immunol Res       Date:  2018-05-17       Impact factor: 4.818

5.  In vivo immunogenicity assessment and vaccine efficacy evaluation of a chimeric tandem repeat of epitopic region of OMP31 antigen fused to interleukin 2 (IL-2) against Brucella melitensis in BALB/c mice.

Authors:  Narges Nazifi; Mojtaba Tahmoorespur; Mohammad Hadi Sekhavati; Alireza Haghparast; Ali Mohammad Behroozikhah
Journal:  BMC Vet Res       Date:  2019-11-08       Impact factor: 2.741

6.  Proteome-wide analysis of Coxiella burnetii for conserved T-cell epitopes with presentation across multiple host species.

Authors:  Lindsay M W Piel; Codie J Durfee; Stephen N White
Journal:  BMC Bioinformatics       Date:  2021-06-02       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.